Oral immunotherapy using boiled peanuts for treating peanut allergy: An open-label, single-arm trial

被引:10
|
作者
Grzeskowiak, Luke E. [1 ,2 ,5 ]
Tao, Billy [1 ,3 ]
Aliakbari, Kamelya [1 ]
Chegeni, Nusha [1 ]
Morris, Scott [1 ,4 ]
Chataway, Tim [1 ]
机构
[1] Flinders Univ S Australia, Flinders Hlth & Med Res Inst, Coll Med & Publ Hlth, Adelaide, SA, Australia
[2] South Australian Hlth & Med Res Inst, SAHMRI Women & Kids, Adelaide, SA, Australia
[3] Allergy SA, Adelaide, SA, Australia
[4] SA Hlth, Flinders Med Ctr, Dept Neonatal Perinatal Med, Adelaide, SA, Australia
[5] Flinders Univ S Australia, Coll Med & Publ Hlth, GPO Box 2100, Adelaide, SA 5001, Australia
关键词
anaphylaxis; children; desensitization; oral immunotherapy; peanut allergy; safety; MEDIATED FOOD ALLERGY; PREVALENCE; ANAPHYLAXIS; CHALLENGES; CHILDREN;
D O I
10.1111/cea.14254
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
BackgroundPeanut allergy affects 1%-3% of children in Western countries. Boiling peanuts has been demonstrated to result in a hypoallergenic product that may provide a safer way of inducing desensitization in peanut-allergic patients by first inducing tolerance to boiled peanut. We aimed to assess the efficacy and safety of oral immunotherapy (OIT) using sequential doses of boiled peanuts followed by roasted peanuts for treating peanut allergy in children. MethodsIn this open-label, phase 2, single-arm clinical trial, children aged 6-18 years with a positive history of peanut allergy and positive peanut skin prick test >= 8 mm and/or peanut-specific IgE >= 15 kU/L at screening underwent OIT involving sequential up-dosing with 12-hour boiled peanut for 12 weeks, 2-hour boiled peanut for 20 weeks and roasted peanut for 20 weeks, to a target maintenance dose of 12 roasted peanuts daily. Primary outcome: proportion of children passing open-label oral food challenge involving cumulative administration of 12 roasted peanuts (12 g peanuts; approximately 3000 mg peanut protein) 6-8 weeks after reaching the target maintenance dose. Secondary outcomes included treatment-related adverse events and use of medications for treating allergy symptoms. ResultsBetween 1 July 2017 and 22 June 2018, 70 participants were enrolled and commenced OIT. Desensitization was successfully induced in 56 of 70 (80%) participants. Withdrawal due to treatment-related adverse events was infrequent (n = 3). Treatment-related adverse events were reported in 43 (61%) participants, corresponding to a rate of 6.58 per 1000 OIT doses. Medication use associated with treatment-related adverse events was infrequent, with rescue epinephrine use reported by three (4%) participants (0.05 per 1000 doses). ConclusionOral immunotherapy using boiled followed by roasted peanuts represents a pragmatic approach that appears effective in inducing desensitization and is associated with a favourable safety profile.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 50 条
  • [1] Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study
    Vickery, Brian P.
    Vereda, Andrea
    Nilsson, Caroline
    du Toit, George
    Shreffler, Wayne G.
    Burks, A. Wesley
    Jones, Stacie M.
    Fernandez-Rivas, Montserrat
    Bluemchen, Katharina
    Hourihane, Jonathan O'B.
    Beyer, Kirsten
    Smith, Alex
    Ryan, Robert
    Adelman, Daniel C.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (05) : 1879 - +
  • [2] Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
    Fernandez-Rivas, Montserrat
    Vereda, Andrea
    Vickery, Brian P.
    Sharma, Vibha
    Nilsson, Caroline
    Muraro, Antonella
    Hourihane, Jonathan O'b
    DunnGalvin, Audrey
    Toit, George
    Blumchen, Katharina
    Beyer, Kirsten
    Smith, Alex
    Ryan, Robert
    Adelman, Daniel C.
    Jones, Stacie M.
    ALLERGY, 2022, 77 (03) : 991 - 1003
  • [3] Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea
    Petty, Amy J.
    Emge, Drew A.
    Blanchard, Sarah K.
    Selim, Maria Angelica
    Scoggins, Kim
    Liu, Beiyu
    Green, Cynthia L.
    Cardones, Adela R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 390 - 392
  • [4] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10) : 3495 - 3503
  • [5] Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
    Chen, Yuxi
    Pan, Yuan
    Xie, Yanyan
    Shi, Yuxun
    Lu, Yao
    Xia, Yiwen
    Su, Wenru
    Chen, Xiaoqing
    Li, Zuoyi
    Wang, Minzhen
    Miao, Siyu
    Yang, Yating
    Jin, Chenjin
    Luo, Guangwei
    Long, Shixian
    Xiao, Hui
    Huang, Chuangxin
    Zhang, Jian
    Liang, Dan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [6] Patient Satisfaction After Switching to Jatenzo (Oral Testosterone Undecanoate): Update on an Open-label, Single-arm Clinical Trial
    Reddy, Rohit
    Rivero, Marco-Jose
    Patel, Mehul
    Muthigi, Akhil
    Diaz, Parris
    Ramasamy, Ranjith
    EUROPEAN UROLOGY FOCUS, 2023, 9 (01): : 17 - 19
  • [7] Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan
    Morioka, Ichiro
    Kakei, Yasumasa
    Omori, Takashi
    Nozu, Kandai
    Fujioka, Kazumichi
    Takahashi, Naoto
    Yoshikawa, Tetsushi
    Moriuchi, Hiroyuki
    Ito, Yoshinori
    Oka, Akira
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [8] Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy
    Narisety, Satya D.
    Skripak, Justin M.
    Steele, Pamela
    Hamilton, Robert G.
    Matsui, Elizabeth C.
    Burks, A. Wesley
    Wood, Robert A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (03) : 610 - 612
  • [9] Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
    Wang, Jinyuan
    Zhang, Jinlu
    Yu, Shicheng
    Li, Hongyan
    Chen, Shaohong
    Luo, Jingting
    Wang, Haibo
    Guan, Yuxia
    Zhang, Haihan
    Yin, Shiyi
    Wang, Huili
    Li, Heping
    Liu, Junle
    Zhu, Jingyuan
    Yang, Qiong
    Sha, Ying
    Zhang, Chuan
    Yang, Yuhang
    Yang, Xuan
    Zhang, Xifang
    Zhao, Xiuli
    Wang, Likun
    Yang, Liping
    Wei, Wenbin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [10] Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China
    Huang, Li
    Zou, Jun
    Zhang, Yuxin
    Gu, Jiaowei
    Wu, Jianlong
    Zhang, Che
    BMJ OPEN, 2024, 14 (03):